NeoGenomics, Inc. (NEO) – What Are Investment Firms Thinking About This Stock?

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $18.17.

A number of research analysts have recently commented on the company. Zacks Research cut NeoGenomics from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Piper Sandler reissued an “overweight” rating on shares of NeoGenomics in a report on Wednesday. Needham & Company LLC boosted their price objective on NeoGenomics from $19.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, October 6th. Benchmark boosted their price objective on NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Finally, Weiss Ratings raised shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 14th.

Hedge Funds Weigh In On NeoGenomics

Several large investors have recently modified their holdings of the business. First Light Asset Management LLC boosted its holdings in NeoGenomics by 26.2% in the 2nd quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company’s stock worth $179,158,000 after buying an additional 2,549,545 shares during the period. First Trust Advisors LP bought a new stake in NeoGenomics during the 1st quarter valued at $45,725,000. American Capital Management Inc. purchased a new stake in shares of NeoGenomics during the second quarter worth $32,648,000. GW&K Investment Management LLC lifted its position in shares of NeoGenomics by 7.5% during the fourth quarter. GW&K Investment Management LLC now owns 2,238,767 shares of the medical research company’s stock worth $26,328,000 after acquiring an additional 155,882 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of NeoGenomics by 9.2% during the first quarter. Dimensional Fund Advisors LP now owns 2,674,335 shares of the medical research company’s stock worth $19,842,000 after acquiring an additional 225,588 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

NeoGenomics Price Performance

NeoGenomics stock opened at $16.35 on Tuesday. NeoGenomics has a 12 month low of $7.07 and a 12 month high of $20.15. The company has a current ratio of 3.60, a quick ratio of 3.35 and a debt-to-equity ratio of 0.48. The business’s 50 day simple moving average is $17.49 and its 200 day simple moving average is $13.08. The company has a market cap of $2.10 billion, a price-to-earnings ratio of -40.88 and a beta of 1.79.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.02. The business had revenue of $201.66 million during the quarter, compared to analyst estimates of $196.93 million. NeoGenomics had a negative return on equity of 1.99% and a negative net margin of 6.77%. NeoGenomics’s revenue was up 11.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.03 earnings per share. Sell-side analysts forecast that NeoGenomics will post -0.09 EPS for the current year.

About NeoGenomics

NeoGenomics, Inc (NASDAQ:NEO) is a specialized oncology diagnostics company that provides testing services to hospitals, physicians, pathologists, pharmaceutical companies and other healthcare organizations. Its services support the diagnosis, classification and monitoring of cancer, helping guide treatment decisions and drug development.

The company offers a broad range of pathology and laboratory services, including molecular testing, next-generation sequencing, fluorescence in situ hybridization, cytogenetics, flow cytometry, immunohistochemistry and digital pathology.